Predicting cardiovascular events in familial hypercholesterolemia: The SAFEHEART registry (Spanish Familial Hypercholesterolemia Cohort Study)

Circulation

Volumn 135, Issue 22, 2017, Pages 2133-2144

  Pérez De Isla, Leopoldo ^a,b   Alonso, Rodrigo ^b,c   Mata, Nelva ^b,d   Fernández Pérez, Cristina ^a   Muñiz, Ovidio ^e   Díaz Díaz, José Luis ^f   Saltijeral, Adriana ^b,g   Fuentes Jiménez, Francisco ^h   De Andrés, Raimundo ⁱ   Zambón, Daniel ^j   Piedecausa, Mar ^k   Cepeda, José María ^l   Mauri, Marta ^m   Galiana, Jesús ⁿ   Brea, Ángel ^o   Sanchez Muñoz Torrero, Juan Francisco ^p   Padró, Teresa ^q   Argueso, Rosa ^r   Miramontes González, José Pablo ^s   Badimón, Lina ^q   Santos, Raúl D ^t   Watts, Gerald F ^u   Mata, Pedro ^b   more..

^a UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^b Medicina Interna   (Spain)

^c CLÍNICA LAS CONDES   (Chile)

^d Madrid Regional Health and Consumer Affairs Authority   (Spain)

^e HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^f Hospital Abente y Lago   (Spain)

^g UNIVERSIDAD ALFONSO X EL SABIO   (Spain)

^h HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

ⁱ Hospital UniversitarioFundación Jiménez Díaz   (Spain)

^j HOSPITAL CLÍNIC   (Spain)

^k HOSPITAL GENERAL UNIVERSITARIO DE ELCHE   (Spain)

^l HOSPITAL VEGA BAJA   (Spain)

^m HOSPITAL DE TERRASSA   (Spain)

ⁿ Hospital de Ciudad Real   (Spain)

^o HOSPITAL SAN PEDRO   (Spain)

^p HOSPITAL SAN PEDRO DE ALCÁNTARA   (Spain)

^q Centro Cochrane Iberoamericano Instituto de Investigación Biomédica Sant Pau   (Spain)

^r Hospital de Lugo   (Spain)

^s HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

^t UNIVERSITY OF SÃO PAULO   (Brazil)

^u UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

more..

Author keywords

diagnostic techniques, cardiovascular; genetics; heart diseases; hypercholesterolemia; risk assessment

Indexed keywords

EZETIMIBE; HIGH DENSITY LIPOPROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; ARTICLE; BODY MASS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; COHORT ANALYSIS; FAMILIAL HYPERCHOLESTEROLEMIA; FATALITY; FEMALE; FRAMINGHAM RISK SCORE; HUMAN; HYPERTENSION; INCIDENCE; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; MOLECULAR DIAGNOSIS; MULTICENTER STUDY; PREDICTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; SEX DIFFERENCE; SMOKING; CARDIOVASCULAR DISEASES; CLINICAL TRIAL; HYPERLIPOPROTEINEMIA TYPE II; LONGITUDINAL STUDY; MIDDLE AGED; PREDICTIVE VALUE; REGISTER; SPAIN;

ADULT; CARDIOVASCULAR DISEASES; COHORT STUDIES; FEMALE; HUMANS; HYPERLIPOPROTEINEMIA TYPE II; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; REGISTRIES; RISK FACTORS; SPAIN;

EID: 85018840957     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.116.024541     Document Type: Article

References (39)

1. Gidding SS, Champagne MA, de Ferranti SD, Defesche J, Ito MK, Knowles JW, McCrindle B, Raal F, Rader D, Santos RD, Lopes-Virella M, Watts GF, Wierzbicki AS, American Heart Association Atherosclerosis, Hypertension, and Obesity in Young Committee of Council on Cardiovascular Disease in Young, Council on Cardiovascular and Stroke Nursing, Council on Functional Genomics and Translational Biology, and Council on Lifestyle and Cardiometabolic Health The agenda for familial hypercholesterolemia: a scientific statement from the American Heart Association. Circulation 2015 132 2167 2192. doi: 10.1161/CIR.0000000000000297.
2. Nordestgaard BG, Chapman MJ, Humphries SE, Ginsberg HN, Masana L, Descamps OS, Wiklund O, Hegele RA, Raal FJ, Defesche JC, Wiegman A, Santos RD, Watts GF, Parhofer KG, Hovingh GK, Kovanen PT, Boileau C, Averna M, Borén J, Bruckert E, Catapano AL, Kuivenhoven JA, Pajukanta P, Ray K, Stalenhoef AF, Stroes E, Taskinen MR, Tybjærg-Hansen A, European Atherosclerosis Society Consensus Panel Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society. Eur Heart J 2013 34 3478 3390a. doi: 10.1093/eurheartj/eht273.
3. de Ferranti SD, Rodday AM, Mendelson MM, Wong JB, Leslie LK, Sheldrick RC, Prevalence of familial hypercholesterolemia in the 1999 to 2012 United States National Health and Nutrition Examination Surveys (NHANES). Circulation 2016 133 1067 1072. doi: 10.1161/CIRCULATIONAHA.115.018791.
4. Benn M, Watts GF, Tybjaerg-Hansen A, Nordestgaard BG, Familial hypercholesterolemia in the Danish general population: prevalence, coronary artery disease, and cholesterol-lowering medication. J Clin Endocrinol Metab 2012 97 3956 3964. doi: 10.1210/jc.2012-1563.
5. Khera AV, Won HH, Peloso GM, Lawson KS, Bartz TM, Deng X, van Leeuwen EM, Natarajan P, Emdin CA, Bick AG, Morrison AC, Brody JA, Gupta N, Nomura A, Kessler T, Duga S, Bis JC, van Duijn CM, Cupples LA, Psaty B, Rader DJ, Danesh J, Schunkert H, McPherson R, Farrall M, Watkins H, Lander E, Wilson JG, Correa A, Boerwinkle E, Merlini PA, Ardissino D, Saleheen D, Gabriel S, Kathiresan S, Diagnostic yield and clinical utility of sequencing familial hypercholesterolemia genes in patients with severe hypercholesterolemia. J Am Coll Cardiol 2016 67 2578 2589. doi: 10.1016/j.jacc.2016.03.520.
6. Pérez de Isla L, Alonso R, Mata N, Saltijeral A, Muñiz O, Rubio-Marin P, Diaz-Diaz JL, Fuentes F, de Andrés R, Zambón D, Galiana J, Piedecausa M, Aguado R, Mosquera D, Vidal JI, Ruiz E, Manjón L, Mauri M, Padró T, Miramontes JP, Mata P, SAFEHEART Investigators. Coronary heart disease, peripheral arterial disease, and stroke in familial hypercholesterolaemia: insights from the SAFEHEART Registry (Spanish Familial Hypercholesterolaemia Cohort Study). Arterioscler Thromb Vasc Biol 2016 36 2004 2010
7. Scientific Steering Committee on behalf of the Simon Broome Register Group Mortality in treated heterozygous familial hypercholesterolaemia: implications for clinical management. Atherosclerosis 1999 142 105 112
8. Neil A, Cooper J, Betteridge J, Capps N, McDowell I, Durrington P, Seed M, Humphries SE, Reductions in all-cause, cancer, and coronary mortality in statin-treated patients with heterozygous familial hypercholesterolaemia: a prospective registry study. Eur Heart J 2008 29 2625 2633. doi: 10.1093/eurheartj/ehn422.
9. Versmissen J, Oosterveer DM, Yazdanpanah M, Defesche JC, Basart DC, Liem AH, Heeringa J, Witteman JC, Lansberg PJ, Kastelein JJ, Sijbrands EJ, Efficacy of statins in familial hypercholesterolaemia: a long term cohort study. BMJ 2008 337 a2423
10. Baum SJ, Sijbrands EJ, Mata P, Watts GF, The doctor's dilemma: challenges in the diagnosis and care of homozygous familial hypercholesterolemia. J Clin Lipidol 2014 8 542 549. doi: 10.1016/j.jacl.2014.09.005.
11. Everett BM, Smith RJ, Hiatt WR, Reducing LDL with PCSK9 inhibitors: the clinical benefit of lipid drugs. N Engl J Med 2015 373 1588 1591. doi: 10.1056/NEJMp1508120.
12. Jacobson TA, Ito MK, Maki KC, Orringer CE, Bays HE, Jones PH, McKenney JM, Grundy SM, Gill EA, Wild RA, Wilson DP, Brown WV, National Lipid Association recommendations for patient-centered management of dyslipidemia, part 1: executive summary. J Clin Lipidol 2014 8 473 488. doi: 10.1016/j.jacl.2014.07.007.
13. Santos RD, Gidding SS, Hegele RA, Cuchel MA, Barter PJ, Watts GF, Baum SJ, Catapano AL, Chapman MJ, Defesche JC, Folco E, Freiberger T, Genest J, Hovingh GK, Harada-Shiba M, Humphries SE, Jackson AS, Mata P, Moriarty PM, Raal FJ, Al-Rasadi K, Ray KK, Reiner Z, Sijbrands EJ, Yamashita S, International Atherosclerosis Society Severe Familial Hypercholesterolemia Panel Defining severe familial hypercholesterolaemia and the implications for clinical management: a consensus statement from the International Atherosclerosis Society Severe Familial Hypercholesterolemia Panel. Lancet Diabetes Endocrinol 2016 4 850 861. doi: 10.1016/S2213-8587(16)30041-9.
14. Mata N, Alonso R, Badimón L, Padró T, Fuentes F, Muñiz O, Perez-Jiménez F, López-Miranda J, Díaz JL, Vidal JI, Barba A, Piedecausa M, Sanchez JF, Irigoyen L, Guallar E, Ordovas JM, Mata P, Clinical characteristics and evaluation of LDL-cholesterol treatment of the Spanish Familial Hypercholesterolemia Longitudinal Cohort Study (SAFEHEART). Lipids Health Dis 2011 10 94. doi: 10.1186/1476-511X-10-94.
15. Gary S. Collins, Johannes B. Reitsma, Douglas G. Altman, Karel G.M. Moons, Transparent Reporting of a Multivariable Prediction Model for Individual Prognosis or Diagnosis (TRIPOD): the TRIPOD statement. Circulation 2015 131 211 219
16. Watts GF, Gidding S, Wierzbicki AS, Toth PP, Alonso R, Brown WV, Bruckert E, Defesche J, Lin KK, Livingston M, Mata P, Parhofer KG, Raal FJ, Santos RD, Sijbrands EJ, Simpson WG, Sullivan DR, Susekov AV, Tomlinson B, Wiegman A, Yamashita S, Kastelein JJ, Integrated guidance on the care of familial hypercholesterolaemia from the International FH Foundation. Int J Cardiol 2014 171 309 325. doi: 10.1016/j.ijcard.2013.11.025.
17. Alonso R, Andres E, Mata N, Fuentes-Jiménez F, Badimón L, López-Miranda J, Padró T, Muñiz O, Díaz-Díaz JL, Mauri M, Ordovás JM, Mata P, SAFEHEART Investigators Lipoprotein(a) levels in familial hypercholesterolemia: an important predictor of cardiovascular disease independent of the type of LDL receptor mutation. J Am Coll Cardiol 2014 63 1982 1989. doi: 10.1016/j.jacc.2014.01.063.
18. Langsted A, Kamstrup PR, Benn M, Tybjærg-Hansen A, Nordestgaard BG, High lipoprotein(a) as a possible cause of clinical familial hypercholesterolaemia: a prospective cohort study. Lancet Diabetes Endocrinol 2016 4 577 587. doi: 10.1016/S2213-8587(16)30042-0.
19. Alonso R, Defesche JC, Tejedor D, Castillo S, Stef M, Mata N, Gomez-Enterria P, Martinez-Faedo C, Forga L, Mata P, Genetic diagnosis of familial hypercholesterolemia using a DNA-array based platform. Clin Biochem 2009 42 899 903. doi: 10.1016/j.clinbiochem.2009.01.017.
20. Medeiros AM, Alves AC, Bourbon M, Mutational analysis of a cohort with clinical diagnosis of familial hypercholesterolemia: considerations for genetic diagnosis improvement. Genet Med 2016 18 316 324. doi: 10.1038/gim.2015.71.
21. Penning-van Beest FJ, Termorshuizen F, Goettsch WG, Klungel OH, Kastelein JJ, Herings RM, Adherence to evidence-based statin guidelines reduces the risk of hospitalizations for acute myocardial infarction by 40%: a cohort study. Eur Heart J 2007 28 154 159. doi: 10.1093/eurheartj/ehl391.
22. Masana L, Ibarretxe D, Plana N, Maximum low-density lipoprotein cholesterol lowering capacity achievable with drug combinations: when 50 plus 20 equals 60. Rev Esp Cardiol (Engl Ed) 2016 69 342 343
23. Catapano AL, Graham I, De Backer G, Wiklund O, Chapman MJ, Drexel H, Hoes AW, Jennings CS, Landmesser U, Pedersen TR, Reiner Ž Riccardi G, Taskinen MR, Tokgozoglu L, Verschuren WM, Vlachopoulos C, Wood DA, Zamorano JL, 2016 ESC/EAS guidelines for the management of dyslipidaemias: the Task Force for the Management of Dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS) developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Atherosclerosis 2016 253 281 344
24. Perez de Isla L, Alonso R, Watts GF, Mata N, Saltijeral Cerezo A, Muñiz O, Fuentes F, Diaz-Diaz JL, de Andrés R, Zambón D, Rubio-Marin P, Barba-Romero MA, Saenz P, Sanchez Muñoz-Torrero JF, Martinez-Faedo C, Miramontes-Gonzalez JP, Badimón L, Mata P, SAFEHEART Investigators Attainment of LDL-cholesterol treatment goals in patients with familial hypercholesterolemia: 5-year SAFEHEART registry follow-up. J Am Coll Cardiol 2016 67 1278 1285
25. UCLA: Institute for Digital Research and Education What Are Some of the methods for analysing clustered data in Stata? Stata FAQ. http://stats.idre.ucla.edu/stata/faq/what-are-the-some-of-the-methods-for-analyzing-clustered-data-in-stata/. Accessed February 24, 2017.
26. D'Agostino R, Nam BH, Evaluation of the performance of survival analysis models: discrimination and calibration measures. Handbook of Statistics 2004 Amsterdam, the Netherlands Elsevier 1 25
27. Pencina MJ, D'Agostino RB, Overall C as a measure of discrimination in survival analysis: model specific population value and confidence interval estimation. Stat Med 2004 23 2109 2123. doi: 10.1002/sim.1802.
28. Harrell FE Jr, Lee KL, Mark DB, Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med 1996 15 361 387. doi: 10.1002/(SICI)1097-0258(19960229)15:4<361::AID-SIM168>3.0.CO;2-4.
29. D'Agostino RB Sr, Vasan RS, Pencina MJ, Wolf PA, Cobain M, Massaro JM, Kannel WB, General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation 2008 117 743 753. doi: 10.1161/CIRCULATIONAHA.107.699579.
30. D'Agostino RB Sr, Pencina MJ, Massaro JM, Coady S, Cardiovascular disease risk assessment: insights from Framingham. Glob Heart 2013 8 11 23. doi: 10.1016/j.gheart.2013.01.001.
31. Goff DC Jr, Lloyd-Jones DM, Bennett G, Coady S, D'Agostino RB, Gibbons R, Greenland P, Lackland DT, Levy D, O'Donnell CJ, Robinson JG, Schwartz JS, Shero ST, Smith SC Jr, Sorlie P, Stone NJ, Wilson PW, Jordan HS, Nevo L, Wnek J, Anderson JL, Halperin JL, Albert NM, Bozkurt B, Brindis RG, Curtis LH, DeMets D, Hochman JS, Kovacs RJ, Ohman EM, Pressler SJ, Sellke FW, Shen WK, Smith SC Jr, Tomaselli GF, American College of Cardiology/American Heart Association Task Force on Practice Guidelines 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2014 129 suppl 2 S49 S73. doi: 10.1161/01.cir.0000437741.48606.98.
32. Newson RB, Comparing the predictive powers of survival models using Harrell's C or Somers' D. Stata J 2010 3 339 358
33. Besseling J, Kindt I, Hof M, Kastelein JJ, Hutten BA, Hovingh GK, Severe heterozygous familial hypercholesterolemia and risk for cardiovascular disease: a study of a cohort of 14,000 mutation carriers. Atherosclerosis 2014 233 219 223. doi: 10.1016/j.atherosclerosis.2013.12.020.
34. Hegele RA, Improving the monitoring and care of patients with familial hypercholesterolemia. J Am Coll Cardiol 2016 67 1286 1288. doi: 10.1016/j.jacc.2016.01.041.
35. de Sauvage Nolting PR, Defesche JC, Buirma RJ, Hutten BA, Lansberg PJ, Kastelein JJ, Prevalence and significance of cardiovascular risk factors in a large cohort of patients with familial hypercholesterolaemia. J Intern Med 2003 253 161 168
36. Mata N, Alonso R, Banegas JR, Zambón D, Brea A, Mata P, Quality of life in a cohort of familial hypercholesterolemia patients from the south of Europe. Eur J Public Health 2014 24 221 225. doi: 10.1093/eurpub/cks174.
37. Besseling J, Hovingh GK, Huijgen R, Kastelein JJ, Hutten BA, Statins in familial hypercholesterolemia: consequences for coronary artery disease and all-cause mortality. J Am Coll Cardiol 2016 68 252 260. doi: 10.1016/j.jacc.2016.04.054.
38. Besseling J, Kastelein JJ, Defesche JC, Hutten BA, Hovingh GK, Association between familial hypercholesterolemia and prevalence of type 2 diabetes mellitus. JAMA 2015 313 1029 1036. doi: 10.1001/jama.2015.1206.
39. Huijgen R, Vissers MN, Kindt I, Trip MD, de Groot E, Kastelein JJ, Hutten BA, Assessment of carotid atherosclerosis in normocholesterolemic individuals with proven mutations in the low-density lipoprotein receptor or apolipoprotein B genes. Circ Cardiovasc Genet 2011 4 413 417. doi: 10.1161/CIRCGENETICS.110.959239.